PMID- 21865400
OWN - NLM
STAT- MEDLINE
DCOM- 20120113
LR  - 20220409
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Print)
IS  - 1522-8517 (Linking)
VI  - 13
IP  - 10
DP  - 2011 Oct
TI  - A phase II trial of single-agent bevacizumab in patients with recurrent 
      anaplastic glioma.
PG  - 1143-50
LID - 10.1093/neuonc/nor091 [doi]
AB  - The purpose of this study was to evaluate the activity of single-agent 
      bevacizumab in patients with recurrent anaplastic glioma and assess correlative 
      advanced imaging parameters. Patients with recurrent anaplastic glioma were 
      treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations 
      were repeated every 4 weeks. Correlative dynamic contrast-enhanced MR and 
      (18)fluorodeoxyglucose PET imaging studies were obtained to evaluate physiologic 
      changes in tumor and tumor vasculature at time points including baseline, 96 h 
      after the first dose, and after the first 4 weeks of therapy. Median overall 
      survival was 12 months (95% confidence interval [CI]: 6.08-22.8). Median 
      progression-free survival was 2.93 months (95% CI: 2.01-4.93), and 6-month 
      progression-free survival was 20.9% (95% CI: 10.3%-42.5%). Thirteen (43%) 
      patients achieved a partial response. The most common grade >/= 3 treatment-related 
      toxicities were hypertension, hypophosphatemia, and thromboembolism. Single-agent 
      bevacizumab produces significant radiographic response in patients with recurrent 
      anaplastic glioma but did not meet the 6-month progression-free survival 
      endpoint. Early change in enhancing tumor volume at 4 days after start of therapy 
      was the most significant prognostic factor for overall and progression-free 
      survival.
FAU - Kreisl, Teri N
AU  - Kreisl TN
AD  - The Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA. 
      kreislt@mail.nih.gov
FAU - Zhang, Weiting
AU  - Zhang W
FAU - Odia, Yazmin
AU  - Odia Y
FAU - Shih, Joanna H
AU  - Shih JH
FAU - Butman, John A
AU  - Butman JA
FAU - Hammoud, Dima
AU  - Hammoud D
FAU - Iwamoto, Fabio M
AU  - Iwamoto FM
FAU - Sul, Joohee
AU  - Sul J
FAU - Fine, Howard A
AU  - Fine HA
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20110824
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bevacizumab
MH  - Brain Neoplasms/*drug therapy/mortality/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Glioma/*drug therapy/mortality/pathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Positron-Emission Tomography
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3177658
EDAT- 2011/08/26 06:00
MHDA- 2012/01/14 06:00
PMCR- 2012/10/01
CRDT- 2011/08/26 06:00
PHST- 2011/08/26 06:00 [entrez]
PHST- 2011/08/26 06:00 [pubmed]
PHST- 2012/01/14 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - nor091 [pii]
AID - 10.1093/neuonc/nor091 [doi]
PST - ppublish
SO  - Neuro Oncol. 2011 Oct;13(10):1143-50. doi: 10.1093/neuonc/nor091. Epub 2011 Aug 
      24.